Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Neurodegenerative Disorder Therapeutics Market Revenue Growth On Track For A 9.6% CAGR Through 2030
The neurodegenerative disorder therapeutics market has shown substantial growth over the past few years. This market is expected to expand from $21.66 billion in 2025 to $23.65 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.2%. The rise observed in previous periods is attributable to the increasing incidence of neurodegenerative diseases, an expanding elderly population, restricted availability of treatment options, enhanced awareness for prompt diagnosis, and improvements in hospital and neurology care facilities.
The neurodegenerative disorder therapeutics market is projected to experience substantial expansion over the coming years, reaching $34.13 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.6%. This anticipated growth during the forecast period is fueled by several factors, including the progress in gene therapies, improvements in monoclonal antibody treatments, the incorporation of AI-based diagnostics and monitoring systems, increased funding for clinical research and trials, and the broader application of personalized medicine and targeted therapeutics. Key trends expected during this period involve the wider acceptance of neuroprotective and neurorestorative treatments, an increased emphasis on managing symptoms and providing patient-centered care, a rise in clinical trials for new neurodegenerative medications, the proliferation of personalized and targeted therapeutic methods, and the merging of home care with remote monitoring solutions.
Get A Free Sample Report With In-Depth Market Insights:
Neurodegenerative Disorder Therapeutics Market Growth Catalysts And Demand Drivers
Increased investment in research and development (R&D) for neurodegenerative disorder therapeutics is anticipated to drive the expansion of the neurodegenerative disorder therapeutics market moving forward. Governments and organizations are undertaking these R&D investments for neurodegenerative disorders due to various persuasive reasons, such as rising prevalence, significant unaddressed medical requirements, economic ramifications, and global health initiatives. For instance, in March 2023, the Government of Canada, a federal administration based in Canada, announced a $38.3 million investment in 2023 aimed at advancing research into neurodegenerative diseases. Therefore, a continued increase in research and development (R&D) investment for neurodegenerative disorder therapeutics will fuel the growth of the neurodegenerative disorder therapeutics market during the forecast period.
Neurodegenerative Disorder Therapeutics Market Segmentation: How Does The Market Break Down By Category?
The neurodegenerative disorder therapeutics market covered in this report is segmented –
1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types
2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types
3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies
3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids
4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications
5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments
Neurodegenerative Disorder Therapeutics Market Trends Shaping Long-Term Demand
Leading companies within the neurodegenerative disorder therapeutics market are concentrating on developing innovative treatment options, such as prodrug formulations, to enhance the bioavailability, efficacy, and safety profile of Parkinson’s disease therapies. Prodrugs are inactive compounds that the body metabolically converts into active drugs, enabling a controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, introduced PRODUODOPA (foslevodopa or foscarbidopa) in the European Union for individuals living with advanced Parkinson’s disease. This therapy utilizes a soluble prodrug combination to provide continuous levodopa delivery, aiming to reduce motor fluctuations and improve patients’ quality of life. This launch signifies a substantial advancement in managing advanced Parkinson’s disease by offering an alternative to intermittent oral dosing and improving treatment adherence.
Neurodegenerative Disorder Therapeutics Market Competitive Overview And Top Companies
Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.
View The Full Neurodegenerative Disorder Therapeutics Market Report:
Neurodegenerative Disorder Therapeutics Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model